Franck Morschhauser
弗兰克·莫斯豪泽
MD, PhD
Professor of Hematology; Head, Hematology Department血液学教授；血液科主任
👥Biography 个人简介
Prof. Franck Morschhauser is a leading French hematologist specializing in aggressive and indolent B-cell lymphomas. He is best known for leading the POLARIX trial, which demonstrated that polatuzumab vedotin plus R-CHP was superior to R-CHOP in frontline DLBCL, ushering in the first modification to standard therapy in nearly two decades.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
POLARIX Trial — Advancing Frontline DLBCL Therapy
Led the landmark POLARIX phase III trial showing pola-R-CHP significantly improved progression-free survival over R-CHOP in previously untreated DLBCL, establishing the first new frontline standard since 2002.
Representative Works 代表性著作
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma (POLARIX)
New England Journal of Medicine (2022)
Phase III trial showing pola-R-CHP superior PFS to R-CHOP (76.7% vs 70.2% at 2 years) in untreated DLBCL, changing international treatment guidelines.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
关注 弗兰克·莫斯豪泽 的研究动态
Follow Franck Morschhauser's research updates
留下邮箱，当我们发布与 Franck Morschhauser（CHU de Lille — Centre Hospitalier Universitaire de Lille）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment